Document is current
Any future updates will be listed below
-
Authors
Mc Larney, Benedict Edward https://orcid.org/0000-0002-6165-7431
Sonay, Ali Yasin https://orcid.org/0000-0002-2194-9958
Apfelbaum, Elana
Mostafa, Nermin
Monette, Sébastien https://orcid.org/0000-0003-2841-6887
Goerzen, Dana https://orcid.org/0000-0001-9645-3503
Aguirre, Nicole
Exner, Rüdiger M. https://orcid.org/0000-0002-9415-382X
Habjan, Christine
Isaac, Elizabeth
Phung, Ngan Bao https://orcid.org/0000-0002-9452-8089
Skubal, Magdalena
Kim, Mijin https://orcid.org/0000-0002-7781-9466
Ogirala, Anuja
Veach, Darren https://orcid.org/0000-0002-8201-622X
Heller, Daniel A. https://orcid.org/0000-0002-6866-0000
Grimm, Jan https://orcid.org/0000-0002-5282-9385
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering (R56 EB030512, R00-EB033580, R01-EB033651)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA008748, R01-CA215719)
- License Information
-
More Information
Article History
Received: 19 January 2024
Accepted: 21 July 2024
First Online: 9 September 2024
Competing interests
: D.A.H. is a co-founder with equity interest in Lime Therapeutics Inc., Selectin Therapeutics Inc., and Nine Diagnostics Inc.; is a member of the scientific advisory board of Concarlo Therapeutics Inc., Celine Therapeutics Inc., Nanorobotics Inc., and Mediphage Bioceuticals Inc.; and is a consultant for METiS Therapeutics Inc. B.M.L., D.A.H. and J.G. have filed a provisional patent in relation to some of the work in this paper. The other authors declare no competing interests.
